April 23, 2018 / 12:10 PM / 6 months ago

BRIEF-Prothena Discontinues Development Of NEOD001 For Al Amyloidosis

April 23 (Reuters) - Prothena Corporation PLC:

* PROTHENA DISCONTINUES DEVELOPMENT OF NEOD001 FOR AL AMYLOIDOSIS

* PROTHENA DISCONTINUES DEVELOPMENT OF NEOD001 FOR AL AMYLOIDOSIS

* PROTHENA CORPORATION PLC - PHASE 3 VITAL AMYLOIDOSIS STUDY BEING DISCONTINUED BASED ON FUTILITY ANALYSIS

* PROTHENA CORPORATION PLC - PHASE 2B PRONTO STUDY DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below